An analysis of gemcitabine-resistant intrahepatic cholangiocarcinoma cells

ABSTRACT: Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver bile duct cancer with a poor prognosis. For advanced iCCA patients, Gemcitabine (GEM)-based chemotherapy is the standard treatment. Since there is only a 20-30% response rate for advanced CCA patients, it is a critical issue to counteract GEM resistance (GR). We selected two GR iCCA sublines (SSP-25-GR and KKU-213-GR) from the parental cells (SSP-25 and KKU-213) to determine the transcriptome profile.

ORGANISM(S): Homo sapiens

PROVIDER: GSE292343 | GEO | 2026/09/16

REPOSITORIES: GEO